Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...

A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) ...

A panelist discusses how available therapeutic strategies have enhanced their approach to treatment sequencing in patients with polycythemia vera (PV) by providing a broader armamentarium that allows ...

Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

OrthoMinds, LLC ("OrthoMinds") is providing notice of a recent data security event. OrthoMinds is notifying clients and potentially impacted individuals of the event. This notice provides information ...

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...

Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® ...

Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company specializing in peptide-based therapies for blood ...